Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.